Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:U
NYSE:USoftware

Do Confident Analyst Upgrades on Unity (U) Outweigh Insider Selling and AI Competitive Uncertainty?

In recent weeks, Unity Software has attracted renewed attention as multiple research firms reiterated or upgraded positive ratings and raised earnings forecasts, while options activity and analyst commentary underscored expectations for improving margins despite softer revenue growth and sector-wide concern about AI’s impact on software providers. At the same time, investors are weighing upbeat analyst sentiment and stronger earnings estimates against insider share sales and worries that AI...
NasdaqGS:HOOD
NasdaqGS:HOODCapital Markets

A Look At Robinhood Markets (HOOD) Valuation As It Expands With Platinum Card And Tokenized Stocks

Robinhood Markets (HOOD) is drawing fresh attention after launching a high-fee Platinum credit card and rolling out tokenized stocks for European customers. These moves extend its reach beyond traditional trading into payments and crypto infrastructure. See our latest analysis for Robinhood Markets. Despite the new Platinum card and tokenized stocks grabbing headlines, Robinhood’s recent 1-day share price return of 2.62% comes after a tougher stretch, with a 90-day share price return decline...
NasdaqGS:CYTK
NasdaqGS:CYTKBiotechs

Cytokinetics MYQORZO Data Sheds Light On oHCM Outlook And Valuation

Cytokinetics (NasdaqGS:CYTK) presented new clinical data on MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy at a major cardiology conference. The updates covered exercise capacity outcomes, effectiveness across patients with and without hypertension, and safety during treatment interruption and restart. The new analyses expand the clinical profile of MYQORZO, a recently approved oHCM therapy, and add detail on how the drug performs in real treatment scenarios. Cytokinetics...
NYSE:SFBS
NYSE:SFBSBanks

Is ServisFirst Bancshares (SFBS) Offering A Chance After Recent Share Price Weakness

Wondering whether ServisFirst Bancshares is attractively priced at its current level? This article focuses squarely on what the recent share performance might be telling you about value. The stock last closed at US$73.73, with returns of 2.7% year to date, a 14.4% decline over the past month, and a 9.7% decline over the past year, while still showing a 35.2% gain over three years and 31.1% over five years. These mixed returns have kept ServisFirst Bancshares on the radar for investors who...
NasdaqGS:DOCU
NasdaqGS:DOCUSoftware

Is DocuSign (DOCU) Offering Value After Recent Share Price Weakness?

Wondering whether DocuSign at around US$46.82 still lines up with what you would consider a fair price? This article walks through the key valuation checks so you can put the current share price in context. The stock has seen a mixed run recently, with a 3.8% decline over the last 7 days, a 4.5% gain over the last 30 days, and year to date and 1 year returns of 27.8% and 43.9% declines respectively. Recent headlines have continued to focus on DocuSign's role in digital agreement workflows...
NasdaqGS:HALO
NasdaqGS:HALOBiotechs

Could Halozyme (HALO) Returning David Ramsay as Interim CFO Reframe Its ENHANZE Royalty Story?

Halozyme Therapeutics has appointed David Ramsay as interim Chief Financial Officer, effective March 23, 2026, tasking him with overseeing all financial operations while the company continues its search for a permanent CFO. Ramsay’s return, after previously guiding Halozyme from a private business to a billion-dollar public biopharmaceutical company, offers investors continuity in financial leadership during a key transition period. We’ll now examine how Ramsay’s return as interim CFO may...
NYSE:ETSY
NYSE:ETSYMultiline Retail

How Investors Are Reacting To Etsy (ETSY) Refocusing On Reviews And Core Marketplace Operations

Earlier this month, PrintKK announced its integration with Etsy, allowing marketplace sellers to design and sell over 1,000 customizable products globally while PrintKK manages production, packaging, and shipping through its fulfillment network. Around the same time, Etsy overhauled its shop review system to use lifetime reviews with recency weighting and completed the sale of Depop, moves that sharpen focus on marketplace quality and core operations. Next, we’ll examine how Etsy’s shift to...
NYSE:CRM
NYSE:CRMSoftware

A Look At Salesforce (CRM) Valuation As Shares Rebound And AI Potential Is Reassessed

Salesforce stock in focus Salesforce (CRM) is drawing attention after recent share price moves, with the stock last closing at US$198.34. Investors are weighing this level against the company’s current earnings profile and customer relationship management focus. See our latest analysis for Salesforce. The recent 1 day share price return of 2.86% comes after a 90 day share price return of 22.19% and a 1 year total shareholder return decline of 28.89%. This indicates that short term momentum is...
NYSE:GOLD
NYSE:GOLDRetail Distributors

Gold.com Board Shift Brings New Capital Markets Focus For Investors

Gold.com (NYSE:GOLD) has appointed Juan Sartori to its Board of Directors with immediate effect. The move coincides with the retirement of longtime director Beverley Lepine after more than a decade of service. Sartori brings experience in digital finance, commodities, and global capital markets to the company’s board. Gold.com, trading at $46.72, has seen a 34.4% return year to date and a 72.0% return over the past year, with longer term 3 year and 5 year returns of 74.1% and 183.2%...
TSX:CTC.A
TSX:CTC.AMultiline Retail

The Bull Case For Canadian Tire (TSX:CTC.A) Could Change Following New 9.6% Share Buyback Plan

On March 9, 2026, Canadian Tire Corporation, Limited announced a normal course issuer bid to repurchase up to 4,700,000 Class A non-voting shares, or 9.59% of the 49,283,531 shares outstanding as of February 26, 2026, with the program running until March 10, 2027 and repurchased shares returned to authorized but unissued status. The buyback is explicitly intended to counteract dilution from dividend reinvestment and stock option plans, underscoring management’s focus on capital discipline...
TSX:BMO
TSX:BMOBanks

Assessing Bank Of Montreal’s (TSX:BMO) Valuation As Shares Trade Near CA$191 After Mixed Recent Returns

Bank of Montreal stock in focus Bank of Montreal (TSX:BMO) shares are drawing investor attention after recent trading left the stock near CA$191, with a mixed pattern of short term returns and stronger longer term total performance figures. See our latest analysis for Bank of Montreal. Recent trading has been choppy, with a 2.76% 1 day share price return and a softer 7 day and 30 day share price performance. In contrast, the 1 year and 5 year total shareholder returns of 42.27% and 114.04%...
SWX:BANB
SWX:BANBLife Sciences

Bachem Holding (SWX:BANB) Margin Improvement Reinforces Bullish Profitability Narratives

Bachem Holding (SWX:BANB) has just wrapped up FY 2025 with second half revenue of CHF 382.1 million and basic EPS of CHF 1.31, alongside trailing twelve month revenue of CHF 695.1 million and EPS of CHF 1.98 that sit against a 23.7% earnings growth figure for the year. The company has seen revenue move from CHF 605.3 million to CHF 695.1 million on a trailing basis, while EPS has shifted from CHF 1.60 to CHF 1.98. This sets up a story of higher sales translating into improved earnings per...
NasdaqGS:SBUX
NasdaqGS:SBUXHospitality

Assessing Starbucks (SBUX) Valuation After Mixed Share Performance And Slower International Growth Concerns

Recent performance snapshot and why Starbucks is on investors’ radar Starbucks (SBUX) has drawn fresh attention after a mixed run in the stock, with a 1.3% decline over the past day and a 2.0% dip over the past week, contrasting with gains over the past month and past 3 months. Against that backdrop, the company’s latest reported annual figures show revenue of US$37.7b and net income of US$1.4b, with year on year revenue growth of 4.4% and net income growth of 29.1%. See our latest analysis...
SEHK:2145
SEHK:2145Personal Products

Should Shanghai Chicmax Cosmetic’s (SEHK:2145) Bullish 2025 Guidance Driven by KANS and newpage Require Action From Investors?

Shanghai Chicmax Cosmetic Co., Ltd. previously issued unaudited guidance for 2025, indicating expected revenue of about RMB 9,100.0 million to RMB 9,200.0 million and profit of roughly RMB 1,140.0 million to RMB 1,160.0 million, both showing strong year-on-year increases versus 2024. The company linked this outlook to the effectiveness of its multi-brand, multi-category approach, highlighting especially strong momentum from its KANS anti-aging skincare line and its infant-focused newpage...
NYSE:MSI
NYSE:MSICommunications

A Look At Motorola Solutions (MSI) Valuation After Peter Leav’s Board Appointment And Exacom Acquisition

Motorola Solutions (MSI) is back on investors’ radar after the board expanded to add software and cybersecurity veteran Peter Leav, along with the recent Exacom acquisition that deepens its focus on mission-critical public safety technology. See our latest analysis for Motorola Solutions. The recent 2.8% 7 day share price return and 1.9% 30 day share price return have come alongside the Exacom deal and Peter Leav’s board appointment. A 29.4% 90 day share price return and 12.6% 1 year total...
NYSE:LYB
NYSE:LYBChemicals

Will LyondellBasell (LYB) Recast Its Low‑Carbon Story Under New Investor Relations Leadership?

LyondellBasell recently announced that David Dennison, a nearly 30‑year industry veteran who joined the company in 2007 and most recently served as a vice president in its Circular and Low Carbon Solutions business, will become head of investor relations in May 2026, succeeding retiring long‑time executive Dave Kinney. Dennison’s background in planning, commercial leadership and circular solutions could meaningfully shape how LyondellBasell communicates its transition toward recycling,...
NasdaqGS:AVPT
NasdaqGS:AVPTSoftware

How Investors May Respond To AvePoint (AVPT) Launching AgentPulse For Multicloud AI Agent Governance

In early March 2026, AvePoint announced the past general availability of its AgentPulse Command Center, expanding multicloud observability and governance for autonomous AI agents across Microsoft 365 and Google Cloud, with unified monitoring, lifecycle management, and cost controls to reduce shadow AI, data exposure, and surprise usage bills. A distinctive feature is the single-pane view across Copilot Studio, Microsoft Foundry, SharePoint agents, and Vertex AI, giving enterprises...
TASE:RIT1
TASE:RIT1REITs

Reit 1 (TASE:RIT1) One Off Gain Clouds FY 2025 Earnings Narratives

Reit 1 (TASE:RIT1) has released its FY 2025 numbers with fourth quarter revenue of ₪91.1 million and basic EPS of ₪0.89, alongside trailing twelve month EPS of ₪2.53 on revenue of ₪509.9 million. Over the past year, the company has reported profit growth of 69.9% and a net profit margin of 97.5% compared with 59.8% in the prior year, supported in part by a ₪251.2 million one off gain. These results frame a reporting period in which investors may focus on how sustainable these margins are. See...
NYSE:LYV
NYSE:LYVEntertainment

Why Live Nation (LYV) Is Down 5.3% After DOJ Antitrust Settlement And Extended Oversight

Live Nation Entertainment has settled the US Department of Justice’s antitrust lawsuit without admitting wrongdoing, extending its consent decree by eight years and setting up a US$280 million fund to address state damages claims. The agreement lets Live Nation retain Ticketmaster under stricter operating conditions while leaked internal messages and ongoing state actions keep its ticketing practices under intense scrutiny. We’ll now examine how the extended DOJ consent decree and continuing...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

How Diverging Zynyz Outcomes In Cancer Trials At Incyte (INCY) Have Changed Its Investment Story

In early March 2026, Incyte reported a U.S. FDA Complete Response Letter for an additional lung cancer indication of Zynyz due to compliance issues at a third‑party fill‑finish facility, while also securing European Commission approval for Zynyz in combination with chemotherapy as a first‑line treatment for advanced anal cancer. The contrast between a regulatory setback tied to a partner’s manufacturing site in the U.S. and a fresh approval expanding Zynyz’s reach in Europe underscores how...
NasdaqGS:FTDR
NasdaqGS:FTDRConsumer Services

Frontdoor (FTDR) Valuation Check After Strong Q4 Beat And Softer Full Year Guidance

Frontdoor (FTDR) is back in focus after reporting Q4 revenue of $433 million, a 13.1% year over year increase, along with earnings that exceeded expectations and full year revenue guidance slightly below projections. See our latest analysis for Frontdoor. Since the earnings release, Frontdoor’s share price has moved to US$64.22, with a 13.38% 1 month share price return and a 69.58% 1 year total shareholder return, which may suggest building momentum despite some recent short term pullback. If...
NYSE:LEU
NYSE:LEUOil and Gas

Centrus Energy (LEU) Is Up 8.7% After Oklo JV, AI Push Reframe Nuclear Fuel Role – What’s Changed

In March 2026, Oklo Inc. and Centrus Energy agreed to pursue a joint venture for high-assay low-enriched uranium deconversion at Centrus’ Piketon, Ohio site, while Centrus also reported lower-than-expected quarterly earnings affected by a delayed Russian shipment and outlined increased capital spending plans. Centrus’ recent collaboration with Palantir on AI-driven enrichment optimization and its talks with Oklo on an integrated HALEU hub highlight how technology and fuel-cycle partnerships...
NasdaqGS:UBSI
NasdaqGS:UBSIBanks

Is United Bankshares (UBSI) Still Sensibly Priced After The Recent Share Price Pullback?

Wondering if United Bankshares at around US$39.38 is still a fair deal or starting to look stretched? This article breaks down what the current share price might be implying about value. The stock’s returns range from a 1.4% decline over the last 7 days and a 10.7% decline over the last 30 days, to gains of 2.6% year to date, 17.5% over 1 year, 25.7% over 3 years and 25.2% over 5 years. These figures can mean very different things depending on how you think about risk and timing. Recent...
CPSE:ZEAL
CPSE:ZEALBiotechs

Assessing Zealand Pharma (CPSE:ZEAL) Valuation After Positive Petrelintide Phase 2 Obesity Trial Results

Why Zealand Pharma stock is in focus after new obesity trial data Zealand Pharma (CPSE:ZEAL) has moved into the spotlight after announcing that its investigational obesity therapy petrelintide met the primary endpoint in a large Phase 2 trial, showing statistically significant weight loss versus placebo. See our latest analysis for Zealand Pharma. The positive petrelintide data arrives after a difficult period for Zealand Pharma shareholders. A 30 day share price return of 29.15% and a 90 day...